MENU
NGNE
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Neurogene (NGNE) Ownership - Who owns Neurogene?
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning)... Show more
Profile
Industry
N/A
Address
535 W 24th Street
Phone
+1 855 508-3568
Employees
91
Web
https://www.neurogene.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
327.6M
P/E Ratio
N/A
Total Cash
292.6M
Projected Growth
N/A
Total Debt
13.54M
Revenue
925K
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
20.52
Total Debt/Equity
N/A
Revenue/Share
0.05 USD as % of share price
Fundamentals
NGNE
Capitalization
328M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
293M
Total Cash/Share
20.52
Total Debt
13.5M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.05%
Revenue
925K
ROE
N/A
Book Value
292M
P/B Ratio
1.12
Cash Flow
N/A
Earnings
-4.36
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
0
Current Ratio
21.03
Current Revenue Per Employee
10164.83
Dividends Per Share - Security
N/A
EBITDA
-77.68M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-31.67
Shares Held By Institutions
429M
Shares Outstanding - Current
14.3M
Total Liabilities
23.5M
Total Volume MTD
N/A
Value
-1
Gain YTD
0.481
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
535 W 24th Street
Phone
+1 855 508-3568
Employees
91
Web
https://www.neurogene.com